SavedAdd your journal

Journals / Acıbadem Üniversitesi Sağlık Bilimleri Dergisi / 2014 / Sayı: 3

High Mobility Group Box 1 and Cancer

High Mobility Group Box 1 ve Kanser

Mustafa YILDIRIM
Dinç SÜREN
Özlem DEMİRPENÇE
Vildan KAYA
Pages
182–186
Publication Date
2014-09-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Therefore we think that studies that show the role of HMGB1 in prediction of therapy and determining the prognosis are important since they will help determine the types of cancer to be targeted

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: High mobility group box HMGB proteins are non-histone nuclear proteins which have many different functions.
📊
Key Findings & Data:HMGB1 is the most important member of this family.
💡
Conclusion & Impact:Therefore we think that studies that show the role of HMGB1 in prediction of therapy and determining the prognosis are important since they will help determine the types of cancer to be targeted
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:high mobility group box B1 · cancer · apoptosis

Abstract

Aim: High mobility group box HMGB proteins are non-histone nuclear proteins which have many different functions. HMGB1 is the most important member of this family. It binds to the small groove of DNA nonspesifically and modifies the interaction of DNA with some of the transcription factors, including p53 and steroid hormone receptors. HMGB1 is secreted passively from necrotic cells and actively from inflammatory cells and binds to its most important receptor, RAGE receptor for advanced glycation end products . HMGB1 plays a role in cell differantiation, cell migration, tumor metastasis and inflammation. There is increasing evidence on the role of HMGB1 in progression of cancer, angiogenesis, invasion and metastasis. There are studies suggesting that HMGB1 may have an important role in cancer development. Thus, HMGB1 and its receptor RAGE have become important therapy targets. Therefore we think that studies that show the role of HMGB1 in prediction of therapy and determining the prognosis are important since they will help determine the types of cancer to be targeted

Özet

Amaç: High mobility group box HMGB proteinler hücrede çok farklı fonksiyonları olan non-histon nükleer proteinlerdir. HMGB1 bu ailenin en önemli üyesidir. DNA’nın küçük oluğuna nonspesifik şekilde bağlanarak p53, steroid hormon reseptörleri de dahil olmak üzere bazı transkripsiyon faktörlerinin DNA ile etkileşimini modifiye eder. HMGB1‘in nekrotik hücrelerden pasif, inflamatuar hücrelerden aktif olarak sekrete edilerek en önemli reseptörü olan RAGE receptor for advanced glycation end products ’e bağlanır. HMGB1 Hücre farklılaşması, hücre göçü, tümör metastazı ve inflamasyonda da rol oynamaktadır. Kanser progresyonunda, anjiogenezde, invazyon ve metastaz gelişiminde HMGB1 rolü ile ilgili kanıtlar giderek artmaktadır. Yapılan çalışmalar HMGB1‘in kanser gelişiminde önemli bir role sahip olabileceğini düşündürmektedir. Bu nedenle HMGB1 ve reseptörü RAGE önemli bir tedavi hedefi olmaya başlamıştır. Bu nedenle HMGB1’in tedaviyi predikte etme ve prognozu belirlemedeki rolünü aydınlatacak çalışmaların hangi kanserlerin hedeflenebileceğini göstermesi açısından önemli olduğunu düşünüyoruz

🔖

Cite This Article

YILDIRIM, M., SÜREN, D., DEMİRPENÇE, Ö., KAYA, V. (2014). High Mobility Group Box 1 and Cancer. Acıbadem Üniversitesi Sağlık Bilimleri Dergisi, Sayı: 3, 182–186. https://ajindex.com/articles/163020

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Zhang J, McCauley MJ, Maher LJ 3rd, Williams MC, Israeloff NE. Mechanism of DNA flexibility enhancement by HMGB proteins. Nucleic Acids Res 2009;37:1107-14.
  2. Stros M, Polanská E, Struncová S, Pospísilová S. HMGB1 and HMGB2 proteins up-regulate cellular expression of human topoisomerase II alpha. Nucleic Acids Res 2009;37: 2070-86.
  3. Bustin M, Lehn DA, Landsman D. Structural features of the HMG chromosomal proteins and their genes. Biochim Biophys Acta 1990;1049:231-43.
  4. Alexandrova EA, Beltchev BG. Differences between HMG1 proteins isolated from normal and tumour cells. Biochim Biophys Acta 1987;915:399-405.
  5. Alexandrova EA, Beltchev BG. Acetylated HMG1 protein interacts specifically with homologous DNA polymerase alpha in vitro. Biochem Biophys Res Commun 1988;154:918-27.
  6. Kang HJ, Lee H, Choi HJ, Youn JH, Shin JS, Ahn YH, et al. Non-histone nuclear factor HMGB1 is phosphorylated and secreted in colon cancers. Lab Invest 2009;89:948-59.
  7. Müller S, Scaffidi P, Degryse B, Bonaldi T, Ronfani L, Agresti A, et al. New EMBO members’ review: the double life of HMGB1 chromatin protein: architectural factor and extracellular signal. Embo J. 2001;20:4337-40.
  8. Thomas JO, Travers AA. HMG1 and 2, and related ‘architectural’ DNA binding proteins. Trends Biochem Sci 2001;26:167-74.
  9. Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol 2005;5:331-42.
  10. Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002;418:191-5.
  11. Sharma A, Ray R, Rajeswari MR. Overexpression of high mobility group (HMG) B1 and B2 proteins directly correlates with the progression of squamous cell carcinoma in skin. Cancer Invest 2008;26:843-51.
  12. Gnanasekar M, Thirugnanam S, Ramaswamy K. Short hairpin RNA (shRNA) constructs targeting high mobility group box-1 (HMGB1) expression leads to inhibition of prostate cancer cell survival and apoptosis. Int J Oncol 2009;34:425-31.
  13. Yao X, Zhao G, Yang H, Hong X, Bie L, Liu G. Overexpression of high- mobility group box 1 correlates with tumor progression and poor prognosis in human colorectal carcinoma. J Cancer Res Clin Oncol 2010;136:677-84.
  14. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D. Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. Proc Natl Acad Sci USA 2004;101:9309-14.
  15. Court EL, Smith MA, Avent ND, Hancock JT, Morgan LM, Gray AG